We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,953.00
Bid: 6,953.00
Ask: 6,955.00
Change: -57.00 (-0.81%)
Spread: 2.00 (0.03%)
Open: 7,001.00
High: 7,172.00
Low: 6,943.00
Yest. Close: 7,010.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

24 Jun 16 09:49

UPDATE: UK Chemicals And Pharmaceuticals Must "Look To Future"

24 Jun 16 07:44

From beer to drugs to cars: Global business laments EU vote

By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Shocked chief executives from Mumbai to Denver woke up on Friday to face tough decisions over how to respond to Britain's vote to leave the European Union. In Britain itself, businesses as diverse as engineering group Ro

24 Jun 16 06:50

UPDATE 3-U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

(Adds expert's comments) By Ben Hirschler and Julie Steenhuysen LONDON/CHICAGO, June 23 (Reuters) - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effe

23 Jun 16 19:36

UPDATE 2- U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

(Adds details from CDC, background, byline, dateline) By Ben Hirschler and Julie Steenhuysen LONDON/CHICAGO, June 23 (Reuters) - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the na

23 Jun 16 18:00

UPDATE 1-AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

(Adds shares, analyst comment, further details) By Ben Hirschler LONDON, June 23 (Reuters) - AstraZeneca said it would take an $80 million writedown on stocks of its flu vaccine Flumist Quadrivalent, which is sprayed into the nose, after U.S. health authorities decided they would not

23 Jun 16 09:57

UPDATE: AstraZeneca To Take Writedown As FluMist Is Not Recommended

23 Jun 16 09:17

US authorities recommend against AstraZeneca flu vaccine

(ShareCast News) - Pharmaceutical giant AstraZeneca confirmed disappointing news to investors on Thursday, with updated guidance from US regulators recommending against its FluMist Quadrivalent influenza vaccine. The FTSE 100 firm said the updated guidance from the Advisory Committee on Immunization

23 Jun 16 07:32

AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

LONDON, June 23 (Reuters) - AstraZeneca said it would take an $80 million writedown on stocks of its flu vaccine Flumist Quadrivalent, which is sprayed into the nose, after U.S. health authorities decided they would not use the product. The U.S. Centers for Disease Control and Prevention (C

23 Jun 16 06:45

TOP NEWS: AstraZeneca Flu Vaccine Fails To Be Recommended By US Panel

23 Jun 16 06:16

Leave vote would have limited impact on FTSE, says SpreadCo analyst

(ShareCast News) - Although consensus is that the FTSE 100 will rally if voters in the UK opt to remain in the European Union on Thursday and sell off on a Leave vote, the overall impact of an exit on London stocks may be limited, said SpreadCo analyst David Morrison. "The damage to the FTSE100 as a

21 Jun 16 13:12

Hutchison China Expands Savolitinib Trials, Gets AstraZeneca Payment

20 Jun 16 06:41

Broker tips: Imperial Brands, Poundland, Astrazeneca

(ShareCast News) - RBC Capital Markets upgraded Imperial Brands to 'sector perform' from 'underperform' and lifted the price target to 3,700p from 2,900p. The Canadian bank said Imperial's expected full-year 2017 dividend yield of 4.9% is the highest in its coverage and particularly attractive in th

17 Jun 16 12:06

HSBC reiterates 'hold' on Astrazeneca

(ShareCast News) - HSBC reiterated a 'hold' rating on Astrazeneca after the US consumer watchdog increased its drug safety warning of the risk of acute kidney failure for the SGLT-2 inhibitors Farxiga and Invokana. The US Food and Drug Administration (FDA) has revised the warnings in the labels of t

17 Jun 16 10:59

U.S. regulator says too many drugmakers chasing same cancer strategy

14 Jun 16 20:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.